Novel Method for the Detection of pGlu-Abeta Peptides
AssigneeProbiodrug AG
InventorsMartin Kleinschmidt, Torsten Hoffmann, Jens-Ulrich Rahfeld, Stephan Schilling, Beena Punnamoottil, Michael Adler
Life of this patent
Estimating the term…
Abstract
The invention relates to a highly sensitive method for the detection of pGlu-Abeta (pGlu-Aβ) peptides and the use of this method in the diagnosis of neurodegenerative diseases, such as Alzheimer's disease and Mild Cognitive Impairment. The invention further concerns a novel method for monitoring the effectiveness of a treatment of neurode-generative diseases by monitoring changes in the level of pGlu-Aβ peptides.
Claims42
A highly sensitive method for the detection of an Aβ target peptide in a biological sample, comprising a capture reagent which is specific for said Aβ target peptide;
- and an Aβ target peptide detection complex, said method comprising the steps of:
- a) contacting a biological sample with said capture reagent and said detection complex;
- and
- b) detecting said Aβ target peptide;
- wherein the detection complex comprises an Aβ target peptide specific antibody and a nucleic acid marker.
(canceled)
(canceled)
A kit for diagnosing a neurodegenerative disease, such as Alzheimer's disease or Mild Cognitive Impairment, which comprises at least one detection complex, at least one capture antibody and instructions for using the kit, wherein said detection complex comprises, essentially consists of or consists of a detection antibody capable of binding an Aβ target peptide, one or more nucleic acid markers comprising a predetermined nucleotide sequence and at least one first linker molecule adapted to bind said antibody and the nucleic acid marker, and wherein at least one of the detection antibody and the capture antibody specifically binds to the pyroglutamate carrying amino terminus of the Aβ target peptide.
A detection complex comprising, a detection antibody capable of binding an Aβ target peptide, at least one or more nucleic acid marker markers comprising a predetermined nucleotide sequence and at least one first linker molecule adapted to bind said antibody and the nucleic acid marker.
Dependencies are inferred from the claim text.